When researchers study weight-loss interventions, they often focus on total body weight or fat mass. Muscle, or lean mass, tends to get less attention, even though it plays a central role in metabolism, physical function, and long-term health outcomes. A systematic review and meta-analysis published in the International Journal of Obesity set out to fill that gap by pooling data from randomized controlled trials that tested GLP-1 receptor agonists at the doses used for obesity management.
GLP-1 receptor agonists are a class of peptide-based compounds that mimic glucagon-like peptide-1, a hormone the gut releases after a meal. They reduce appetite, slow stomach emptying, and lower blood sugar. What they do to skeletal muscle during extended use is less settled, and that uncertainty motivated this analysis.
The researchers searched PubMed, Embase, and LILACS in March 2025, ultimately including seven randomized controlled trials covering 821 participants. All studies compared a GLP-1 receptor agonist against placebo in people living with obesity. The team used a random-effects statistical model to combine results across studies, accounting for the natural variation between different trial designs and patient populations.
The two numbers that tell different stories
The headline finding is a study in contrasts. On one hand, lean mass as a proportion of total body weight increased by an average of 1.81 percent across the pooled trials. That is a meaningful shift in body composition: for every kilogram of total mass a person carried, more of it was lean tissue at the end of the trial than at the start. The confidence interval ran from 1.1 to 2.52 percent, and statistical heterogeneity between studies was low, meaning the finding was consistent across the included trials.
On the other hand, the absolute amount of lean mass dropped by an average of 1.74 kilograms. Put plainly, participants lost real muscle tissue, even as the proportion of their bodies made up by muscle went up. How can both be true at once? The answer lies in arithmetic. When total body weight falls substantially, fat typically accounts for most of that loss. If fat shrinks faster than muscle, muscle becomes a larger share of a smaller total, even though the absolute quantity of muscle has declined.
Why the distinction matters
Understanding the difference between relative and absolute lean mass is not just a statistical footnote. For researchers thinking about metabolic health, muscle function, and physical capacity, absolute lean mass matters. Losing nearly two kilograms of muscle tissue on average is a measurable change that could affect strength, resting metabolic rate, and physical independence, particularly in older adults.
At the same time, relative lean mass, meaning the fraction of the body made of muscle and other lean tissue, carries its own clinical weight. A higher lean-to-fat ratio is generally associated with better insulin sensitivity and metabolic markers. So the picture that emerges from the meta-analysis is genuinely mixed: body composition shifts in a favorable direction on a proportional basis, but some absolute muscle is lost in the process.
The review authors were direct about this tension. Their conclusion was that lean mass loss should not be treated as a reason to avoid these compounds in people with obesity, but they also underscored that the drug alone is unlikely to produce the best outcome. Nutritional support and structured physical exercise were highlighted as important complements to any pharmacological approach.
Variation across the peptide subtype studied most
Not every GLP-1 receptor agonist performed identically in the pooled data. The compound with the most evidence in the analysis showed the largest reduction in absolute lean mass, averaging 5.44 kilograms lost. The confidence interval for that figure ran from roughly 3.8 to 7.1 kilograms, and the result was statistically strong.
The authors noted that this compound also tended to produce greater overall weight loss in the trials, which may partly explain why the absolute lean mass reduction was larger. More total weight lost means more opportunity for lean tissue to be included in that loss. Whether the ratio of muscle loss to fat loss is inherently different for this compound compared with others in the class is a question the current data cannot fully resolve, partly because heterogeneity between studies was high for absolute lean mass outcomes.
High heterogeneity, reflected in an I-squared value of 98 percent for both absolute lean mass change and percentage lean mass change, signals that the individual trials differed substantially in their results. That kind of variation can come from differences in trial duration, participant age and fitness level, dietary guidance offered alongside treatment, and how lean mass was measured. The low heterogeneity seen only for the proportional lean mass outcome suggests that relative body composition shift is a more consistent finding across different study conditions.
The role of exercise and nutrition in the research context
Several of the included trials combined the peptide treatment with lifestyle interventions, while others did not, and this variation likely contributed to the spread in results. The review authors emphasized that the existing literature consistently points toward resistance exercise and adequate protein intake as protective factors for muscle mass during any energy-deficit period, including weight loss driven by GLP-1 receptor agonists.
This is an area where researchers say more targeted trials are needed. Most of the seven studies included in this meta-analysis were not designed primarily to test muscle preservation strategies alongside the peptide treatment. Future research that specifically randomizes participants to exercise protocols or protein supplementation in combination with GLP-1 receptor agonist treatment would help clarify how much of the lean mass loss is preventable.
Limitations the authors acknowledged
Seven studies and 821 participants is a modest base of evidence for confident conclusions. The authors were transparent about this. The high statistical heterogeneity in absolute lean mass outcomes means pooled averages should be interpreted with caution rather than applied universally. Different measurement techniques for lean mass, ranging from DEXA scans to bioelectrical impedance, introduce variability in how results translate across studies.
The meta-analysis also focused on obesity-management doses, so the findings do not necessarily extend to lower doses used for blood sugar management alone, or to populations without obesity. Trial durations varied, and longer-term data on whether lean mass stabilizes after an initial adjustment period, or continues to decline, are not yet available in sufficient volume to draw conclusions.
Despite these caveats, the analysis represents the most comprehensive pooling of randomized trial data on this question to date. Its consistency on the proportional lean mass outcome, combined with the clear signal of absolute lean mass loss, gives researchers a clearer picture than any single trial could provide.
What this means for the research landscape
The findings from this meta-analysis are relevant for anyone following the science of metabolic peptides and body composition research. They reinforce a broader principle that weight loss interventions, whether pharmacological or otherwise, rarely affect fat and muscle in a perfectly selective way. The body's response to a prolonged energy deficit involves lean tissue to some degree, and understanding how to minimize that loss while maximizing fat reduction is an active area of inquiry.
Peptide researchers studying compounds that interact with energy metabolism, appetite regulation, or muscle protein synthesis pathways may find this data useful as a comparison baseline. The literature suggests that the combination of GLP-1 receptor agonist treatment with exercise, particularly resistance training, and appropriate protein intake offers the most favorable body composition profile based on available evidence. Controlled trials specifically designed to test that combination at various doses and durations remain a meaningful gap in the current literature.
